Phase I Study of Alternating Doublets of Topotecan/Carboplatin and Paclitaxel/Carboplatin in Patients with Newly Diagnosed, Advanced Ovarian Cancer

By Gordon A.N.   Hancock K.C.   Matthews C.M.   Messing M.   Stringer C.A.   Doherty M.G.   Teneriello M.  

Gynecologic Oncology, Vol. 85, Iss. 1, 2002-04 ,pp. : 129-135

Elsevier

Access to resources Recommend Favorite

Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer

By Bolis G.   Scarfone G.   Villa A.   Parazzini F.  

Gynecologic Oncology, Vol. 81, Iss. 2, 2001-05 ,pp. : 331-333

Elsevier

Access to resources Recommend Favorite

Repetitive High-Dose Topotecan, Carboplatin, and Paclitaxel with Peripheral Blood Progenitor Cell Support in Previously Untreated Ovarian Cancer: Results of a Phase I Study

By Prince H.M.   Rischin D.   Quinn M.   Allen D.   Planner R.   Neesham D.   Gates P.   Davison J.  

Gynecologic Oncology, Vol. 81, Iss. 2, 2001-05 ,pp. : 216-224

Elsevier

Access to resources Recommend Favorite

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer

By Sehouli Jalid   Camara Oumar   Mahner Sven   Bauknecht Thomas   Lichtenegger Werner   Runnebaum Ingo   Look Katherine   Jaenicke Fritz   Oskay-Oezcelik Guelten  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 5, 2010-10 ,pp. : 861-868

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation

By                  

International Journal of Oncology, Vol. 40, Iss. 3, 2012-01 ,pp. : 773-781

Spandidos Publications

Access to resources Recommend Favorite